ANNX•benzinga•
Annexon Says Tanruprubart Met The Primary Endpoint; Demonstrates Rapid, Durable Recovery and Superior Efficacy In First Placebo-Controlled Phase 3 GBS Trial, Showing Significant Improvement In Motor Function, Mobility, and Disability Measures Over Placebo
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga